Christopher J. Senner Exelixis, Inc. (EXEL) insider trading activity

Christopher J. Senner is EVP and CFO of EXELIXIS, INC.. Currently has a direct ownership of 721,680 shares of EXEL, which is worth approximately $26.2 Million. The most recent transaction as insider was on Aug 09, 2024, when has been sold 125,000 shares (Common Stock) at a price of $27.19 per share, resulting in proceeds of $3,398,750. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 722K

0% 3M change

18.01% 12M change

Total Value Held $26.2 Million

Christopher J. Senner Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Aug 09 2024	SELL Open market or private sale	$3,398,750 $27.19 p/Share	125,000 Reduced 14.76%	721,680 Common Stock
Aug 09 2024	BUY Exercise of conversion of derivative security	$3,051,250 $24.41 p/Share	125,000 Added 12.86%	846,680 Common Stock
May 15 2024	SELL Payment of exercise price or tax liability	$636,206 $20.99 p/Share	30,310 Reduced 4.03%	721,680 Common Stock
Feb 23 2024	BUY Grant, award, or other acquisition	-	82,121 Added 9.85%	751,990 Common Stock
Jan 11 2024	SELL Payment of exercise price or tax liability	$499,765 $22.86 p/Share	21,862 Reduced 3.16%	669,869 Common Stock
Jan 11 2024	BUY Grant, award, or other acquisition	-	80,186 Added 10.39%	691,731 Common Stock
Sep 06 2023	SELL Payment of exercise price or tax liability	$381,863 $22.27 p/Share	17,147 Reduced 2.73%	611,545 Common Stock
Sep 06 2023	BUY Grant, award, or other acquisition	-	65,135 Added 9.39%	628,692 Common Stock
Aug 15 2023	SELL Payment of exercise price or tax liability	$173,671 $21.51 p/Share	8,074 Reduced 1.41%	563,557 Common Stock
Aug 04 2023	SELL Open market or private sale	$1,240,800 $20.68 p/Share	60,000 Reduced 9.5%	571,631 Common Stock
Aug 04 2023	BUY Exercise of conversion of derivative security	$884,400 $14.74 p/Share	60,000 Added 8.68%	631,631 Common Stock
Aug 03 2023	SELL Open market or private sale	$1,230,600 $20.51 p/Share	60,000 Reduced 9.5%	571,631 Common Stock
Aug 03 2023	BUY Exercise of conversion of derivative security	$884,400 $14.74 p/Share	60,000 Added 8.68%	631,631 Common Stock
May 15 2023	SELL Payment of exercise price or tax liability	$353,794 $19.18 p/Share	18,446 Reduced 3.13%	571,631 Common Stock
Apr 03 2023	BUY Grant, award, or other acquisition	-	85,414 Added 12.64%	590,077 Common Stock
Feb 15 2023	SELL Payment of exercise price or tax liability	$95,426 $18.08 p/Share	5,278 Reduced 1.04%	504,663 Common Stock
Nov 15 2022	SELL Payment of exercise price or tax liability	$134,916 $16.71 p/Share	8,074 Reduced 1.56%	509,941 Common Stock
Aug 11 2022	SELL Payment of exercise price or tax liability	$2,939,632 $19.23 p/Share	152,867 Reduced 22.79%	518,015 Common Stock
Aug 11 2022	BUY Exercise of conversion of derivative security	$1,397,250 $6.21 p/Share	225,000 Added 25.11%	670,882 Common Stock
Aug 03 2022	SELL Payment of exercise price or tax liability	$173,510 $21.49 p/Share	8,074 Reduced 1.78%	445,882 Common Stock
Aug 03 2022	BUY Grant, award, or other acquisition	-	32,567 Added 6.69%	453,956 Common Stock
May 15 2022	SELL Payment of exercise price or tax liability	$169,556 $20.08 p/Share	8,444 Reduced 1.96%	421,389 Common Stock
Mar 04 2022	BUY Grant, award, or other acquisition	-	75,985 Added 15.02%	429,833 Common Stock
Feb 15 2022	SELL Payment of exercise price or tax liability	$340,699 $18.59 p/Share	18,327 Reduced 4.92%	353,848 Common Stock
Dec 15 2021	SELL Payment of exercise price or tax liability	$87,227 $17.0 p/Share	5,131 Reduced 1.36%	372,175 Common Stock

Also insider at

CRTX

Cortexyme, Inc. Healthcare

CJS